A 2-Part, Single-Dose Study to Evaluate the Interaction of Etoricoxib and Tizanidine Modified Release (MR) when Co-administered or Administered Alone in Healthy Subjects

Trial Profile

A 2-Part, Single-Dose Study to Evaluate the Interaction of Etoricoxib and Tizanidine Modified Release (MR) when Co-administered or Administered Alone in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Etoricoxib (Primary) ; Tizanidine (Primary)
  • Indications Acute pain; Ankylosing spondylitis; Dysmenorrhoea; Gout; Muscle spasticity; Musculoskeletal pain; Osteoarthritis; Postoperative pain; Rheumatic disorders; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 23 May 2013 Status changed from active, no longer recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
    • 08 Apr 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.
    • 25 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top